有报道称，生物技术巨头渤健公司计划以约56亿美元的价格收购Apellis Pharmaceuticals Inc.，旨在增强其在肾脏疾病治疗领域的业务布局。受此消息提振，Apellis公司股价在盘前交易时段应声飙升，涨幅超过100%。
此次潜在收购若最终达成，将显著扩大渤健公司在肾病治疗产品线方面的实力。市场分析认为，此举反映了大型制药企业通过并购具有创新疗法的小型生物技术公司来补充产品管线的战略趋势。
- Like
- Comment
- Favorite
传渤健56亿美元收购Apellis强化肾病业务，后者股价盘前暴涨逾一倍
美股速递03-31
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Like
Report
Login to post
No comments yet